Tag Archives: San Francisco

Redefining Early Stage Investments Conference Series – San Francisco 2017 Program Guide Announced

5 Jan

By Nono Hu, Director of Marketing, LSN

LSN is looking forward to hosting the 11th Redefining Early Stage Investments Conference (RESI) during San Francisco’s annual healthcare conference week. At RESI, over 450 investors will be under one roof in search of compelling connections with early stage companies.

LSN would like to present the RESI San Francisco 2017 Program Guide. If you’re planning your day at RESI SF and want to see full lists of the investor panel speakers, RESI Innovation Challenge finalists and service providers you could meet, look no further!

resi-sf-program-guide-wp

Tags: , , ,

RESI San Francisco Panel Announcement: Tech Giants in Healthcare

29 Dec

By Michael Quigley, VP of Market Research, LSN

mike-2

Large technology companies have been expanding their footprint in the healthcare sector through venture investment and partnerships into early stage healthcare companies. Often seeking technology with a significant software component, many of these groups have helped to fuel the massive growth that has been seen in the digital health space in the past few years. From patient monitoring devices to mobile 3D imaging devices the lines between pure tech and healthcare are slowly beginning to blur as healthcare providers continually look to improve care while lowering costs.

Moderated by Michael Greeley, General Partner, Flare Capital Partners, the panelists are:

  • Iana Dimkova, Senior Associate, Healthcare, GE Ventures
  • Lucian Iancovici, FACHE, Head of Qualcomm Life Fund, Qualcomm Ventures
  • Rich Wilmot, Head of Corporate Venturing, Philips
  • Ying Tam, Head, Digital Health Cluster, Venture Services, MaRS

In this session, a number of investors at these large firms will discuss their involvement in healthcare innovation ecosystem. What types of technologies they are interested in? How much data do they like to see pre-investment? What problems in the space are they looking to tackle? These questions and more will be answered at RESI on Jan 10th so if you’re looking to partner with a large tech company for your product this is a panel you don’t want to miss.

Tags: , , , , , , ,

RESI San Francisco Panel Announcement: Biotech Family Offices

15 Dec

By Lucy Parkinson, Director of Research, LSN

RESI has always aimed to represent the diversity of capital sources for early stage life science companies; alongside sessions featuring VCs, pharma, angels, and other traditional sources of capital, LSN is proud to feature two sessions devoted to Family Offices that invest in new healthcare ventures. The Biotech Family Office sesssion features investors from five different firms who will cover the wide-ranging interests of family offices in the early stage drug development sector.

Moderated by Jayson Rieger (SVP of Business Development & Portfolio Management, PBM Capital), the panelists are:

Christine Bunt (Venture Partner, 20/20 HealthCare Partners)
Will Eden (Vice President, Thiel Capital)
Daron Evans (Managing Director, PoC Capital)
Alex Pickett (Associate, Mediqventures)

If you’d be interested in hearing how these family offices source and assess biotech opportunities, and what you need to do to align your company with their investment ethos, you can register for RESI now.

resi-san-francisco-2017

Tags: , , , , , , ,

RESI San Francisco Panel Announcement: Big Pharma

10 Nov

By Cole Bunn, Senior Research Analyst, LSN

cole-wp

As we gear up for the biggest RESI event of the year, during the heavily anticipated JPM week, we’re happy to once again announce the Big Pharma panel. This is typically one of the most popular panels at the RESI conference, and for good reason – large pharmaceutical and biotech companies, through a variety of deal structures, are looking earlier and earlier for assets, but tend to represent a daunting challenge for entrepreneurs seeking to successfully engage and navigate.

Senior-level executives from some of the world’s top pharmaceutical companies will provide some color around their process and strategy, and how entrepreneurs can best prepare to present to and work with organizations like theirs.

Big Pharma panelists will include the following:

  • Monica Viziano, Sr. Director, Business Development, Gilead
  • Barbara Sosnowski, VP External R&D Innovation, Pfizer
  • Lesley Stolz, Head, JLABS California, Johnson & Johnson Innovation
  • Christian Schubert, Director, Corporate Development & Strategy, Biogen
  • Jeremy Grunstein, Executive Director, Business Development, Amgen

By registering for RESI San Francisco on January 10 (Tuesday of JPM week), you’ll be able to listen to this panel live and gain insight into the dynamics of partnering with a strategic player as well as experience numerous opportunities to expand your network in the life sciences and learn more about the fundraising process in general.

resi-san-francisco-2017

Tags: , , , , , , ,

RESI San Francisco Panel Announcement: Corporate VCs & Strategic Investment

3 Nov

By Lucy Parkinson, Director of Research, LSN

Major pharma firms are increasingly looking externally for innovative technologies, and strategic venture investments are a key part of many firms’ strategies for participating in the early stage ecosystem.  Firms may use subsidiary corporate venture funds, or may have an internal unit for making strategic investments in startups that are relevant to their pipeline.

At RESI San Francisco on Tuesday January 10th, the Corporate VC panel will bring together investors from 5 different corporate VCs to cover how they invest on behalf of their parent pharma companies.

The panelists are:

In this panel, corporate VC investors will discuss the types of companies they’re interested in investing in, and how they structure these opportunities to achieve their strategic aims. Panelists will provide advice on how entrepreneurs can engage with a corporate investor, and how they bridge the gap between early stage startups and major pharmaceutical corporations.

If you’d like to be there in person, you can register for RESI now.

resi-san-francisco-2017

Tags: , , , , , , , , ,

RESI San Francisco 2017 Panel Announcement: Early Stage Therapeutics Investors

27 Oct

By Caitlin Kramer, Research Analyst, LSN

caitlin-wp

The critical early years of drug development after lead compound selection see pre-clinical studies, IND-filing, and the design and implementation of clinical trials. While navigating the regulatory needs of the FDA may seem enough of a challenge, entrepreneurs must also consider how their drug addresses the needs of investors. Capital intensity, endpoint selection, timelines to inflection points – these are just a few topics beyond the scientific data that LSN researchers have discussed the importance of with investors.

Understanding what investors are looking for in the deal and business plan structure can help entrepreneurs immensely in their approach to funding. LSN is pleased to announce the Early Stage Therapeutics Investors panel for RESI SF 2017, where five therapeutics investors will share their perspective on evaluating deals and answer audience questions.

Joining moderator Doug Fisher, Partner, InterWest Partners:

Check out these investors’ bios, and if you haven’t registered yet, do so here or get in touch with us by reaching out to the RESI team at RESI@lifesciencenation.com.

237521341025992000

resi-san-francisco-2017

Tags: , , , , , , ,

The Investors You’ll Meet at RESI San Francisco

20 Oct

By Caitlin Kramer, Research Analyst, LSN

caitlin-wp

Registration for RESI SF 2017 has been open for only a little over a month, and already 239 investors across 158 firms are registered. To illustrate who these 158 firms are, the below shows a breakdown of registered investment firm categories. VC firms have a large showing, followed by Corporate Venture groups and large pharmaceutical/biotech companies active in equity investing and early stage partnering.

 

Click to See More Confirmed Investors

Of the 239 investors registered thus far, 67% have a decision maker role at their firm, such as Director, VP, Partner or a C-Suite title. Only 16% are entry level investment professionals responsible for sourcing and preliminary screening. Of the remainder, most hold other managerial and sourcing roles; in addition, 6% of the investor attendees are angel investors. This abundance of active early stage life science investors and decision makers is unparalleled. Check out the below list of investors that have already registered, and keep in mind that many more will be added in the months leading up to the date of RESI SF on January 10th. We add new confirmed investors to the website every few days – keep up to date here.  You have until Friday October 21st to sign up for RESI at the Earlybird rate – that’s tomorrow!

162801425610010374

resi-san-francisco-2017

 

Tags: , , ,

← Older Entries
Newer Entries →